NCT00663403View on ClinicalTrials.gov

Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Critically IllHemodialysis
Interventions
DRUG

Daptomycin

Daptomcyin 8 mg/kg infused intravenously every 48 hours

Trial Locations (1)

48109

University of Michigan University Hospital, Ann Arbor

All Listed Sponsors
collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

University of Michigan

OTHER

NCT00663403 - Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) | Biotech Hunter | Biotech Hunter